Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Viking Therapeutics, Inc. | vktx-10k_20191231.htm |
| EX-32.1 - EX-32.1 - Viking Therapeutics, Inc. | vktx-ex321_11.htm |
| EX-31.2 - EX-31.2 - Viking Therapeutics, Inc. | vktx-ex312_8.htm |
| EX-31.1 - EX-31.1 - Viking Therapeutics, Inc. | vktx-ex311_6.htm |
| EX-4.5 - EX-4.5 - Viking Therapeutics, Inc. | vktx-ex45_173.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements of Viking Therapeutics, Inc. on Form S-8 (File Nos. 333-203810, 333-211270, 333-216857, 333-223503 and 333-230247), on Form S-3 (File Nos. 333-212134, 333-216063 and 333-226133) and on Form S-1 (File Nos. 333-213496, 333-220992 and 333-222202) of our report dated February 26, 2020 with respect to our audits of the financial statements of Viking Therapeutics, Inc. as of December 31, 2019 and 2018 and for the years then ended, which report is included in this Annual Report on Form 10-K of Viking Therapeutics, Inc. for the year ended December 31, 2019.
Our report on the financial statements refers to a change in the method of accounting for leases effective January 1, 2019.
/s/ Marcum LLP
Marcum LLP
Costa Mesa, California
February 26, 2020